Liraglutide vs Semaglutide: When the Older GLP-1 Still Fits

The basic comparison

Liraglutide — GLP-1 receptor agonist, FDA-approved 2010 (Victoza for diabetes) and 2014 (Saxenda for obesity). Daily subcutaneous injection. Half-life: ~13 hours. Maximum doses: 1.8 mg daily (Victoza), 3.0 mg daily (Saxenda).

Semaglutide — GLP-1 receptor agonist, FDA-approved 2017 (Ozempic for diabetes), 2019 (Rybelsus oral for diabetes), 2021 (Wegovy for obesity). Once-weekly subcutaneous (Ozempic, Wegovy) or daily oral (Rybelsus). Half-life: ~7 days for injectable. Maximum doses: 2 mg (Ozempic), 2.4 mg (Wegovy), 14 mg (Rybelsus).

Both are GLP-1 mono-agonists with the same general mechanism. The differences are in pharmacokinetics, dose ranges, and the resulting efficacy and convenience profiles.

Efficacy comparison

Semaglutide produces meaningfully more weight loss than liraglutide. Head-to-head and parallel trials:

• SUSTAIN-10 compared semaglutide vs. liraglutide in T2D — semaglutide produced greater HbA1c reduction and weight loss
• STEP-8 compared semaglutide 2.4 mg vs. liraglutide 3.0 mg in obesity — semaglutide produced ~15% weight loss vs. ~6% for liraglutide
• Trial-to-trial comparisons place liraglutide weight loss at roughly 5-8% range, semaglutide at 13-15%

For pure weight-loss magnitude, semaglutide is clearly superior. Glycemic control also favors semaglutide in head-to-head data.

Where liraglutide still fits

Daily dose titration. Liraglutide's daily dosing allows faster titration adjustments. Patients who need to slow or reverse dose escalation due to side effects can make small adjustments daily rather than weekly. For some patients, this granularity matters.

Shorter half-life — quicker clearance. If you need to stop GLP-1 therapy quickly (planned surgery, unexpected pregnancy, severe adverse event), liraglutide clears in days. Semaglutide takes weeks to fully clear. For situations where rapid washout matters, liraglutide is advantageous.

Pediatric obesity indication. Saxenda has FDA approval for ages 12+. Wegovy gained pediatric approval later (2022), but liraglutide has the longer pediatric track record.

Longer cardiovascular outcomes track record. LEADER (2016) was one of the earliest GLP-1 cardiovascular outcomes trials. Semaglutide's SUSTAIN-6 and SELECT data is now more recent and arguably stronger, but liraglutide's evidence base spans more years of real-world use.

Cost in some markets. Generic liraglutide became available in some countries earlier than semaglutide; in markets where liraglutide is generic and semaglutide isn't, cost dynamics may favor liraglutide for cost-constrained patients.

Patients who can't tolerate weekly injection variability. A small subset of patients prefer the steady-state pharmacology of daily dosing over the once-weekly pattern that involves peak-and-trough dynamics within the week.

Where semaglutide wins clearly

Weight loss magnitude. Substantially more.

Glycemic control. Substantially more in T2D.

Convenience. Once-weekly injection beats daily injection for most patients on long-term therapy.

Strongest CV evidence in obesity. SELECT (2023) established CV benefit in obesity without diabetes — this is unique to semaglutide.

Most expansive coverage. The semaglutide cardiovascular and renal evidence base (SELECT, FLOW, SUSTAIN-6) is the most comprehensive in the GLP-1 class.

Special situations

Pre-surgery washout: If you have planned surgery, liraglutide's faster washout may matter. GLP-1 medications affect gastric emptying and have implications for anesthesia. Some surgical guidelines recommend holding GLP-1s before surgery; the shorter washout window of liraglutide is operationally simpler.

Pregnancy planning: GLP-1 medications aren't recommended during pregnancy. If pregnancy is on the horizon, liraglutide's faster clearance allows quicker washout if needed.

Pediatric: Saxenda for ages 12+ has the longer indication history; both Saxenda and Wegovy now have pediatric approvals.